MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer

Core Insights - MAIA Biotechnology has initiated the first patient dosing in the THIO-104 Phase 3 pivotal trial for ateganosine, a treatment for advanced non-small cell lung cancer (NSCLC) [1][3] - The trial aims to compare the overall survival of ateganosine sequenced with a checkpoint inhibitor against chemotherapy in patients resistant to previous treatments [2][6] - The FDA has granted Fast Track designation for ateganosine, indicating its potential significance in treating NSCLC [4] Company Overview - MAIA Biotechnology is focused on developing targeted immunotherapies for cancer, with ateganosine as its lead program targeting telomeres in cancer cells [5][8] - The company aims to improve survival rates for NSCLC patients, with Phase 2 data showing a median survival of 17.8 months for ateganosine compared to approximately six months for chemotherapy [3][5] Clinical Trial Details - The THIO-104 trial is a multicenter, open-label study designed to enroll up to 300 patients, assessing the efficacy and safety of ateganosine in combination with a checkpoint inhibitor [2][6] - The primary endpoint of the trial is median overall survival, with safety and tolerability also being evaluated [6]